Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Return on Sales (2016 - 2025)

Historic Return on Sales for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to 1.27%.

  • BioCorRx's Return on Sales rose 1849300.0% to 1.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.5%, marking a year-over-year increase of 1817000.0%. This contributed to the annual value of 679.99% for FY2024, which is 6377000.0% down from last year.
  • Latest data reveals that BioCorRx reported Return on Sales of 1.27% as of Q3 2025, which was up 1849300.0% from 7.73% recorded in Q2 2025.
  • Over the past 5 years, BioCorRx's Return on Sales peaked at 1.27% during Q3 2025, and registered a low of 679.99% during Q4 2024.
  • In the last 5 years, BioCorRx's Return on Sales had a median value of 67.56% in 2021 and averaged 124.29%.
  • Per our database at Business Quant, BioCorRx's Return on Sales plummeted by -6288200bps in 2024 and then skyrocketed by 3355300bps in 2025.
  • BioCorRx's Return on Sales (Quarter) stood at 93.23% in 2021, then surged by 85bps to 14.03% in 2022, then tumbled by -265bps to 51.17% in 2023, then plummeted by -1229bps to 679.99% in 2024, then soared by 100bps to 1.27% in 2025.
  • Its Return on Sales stands at 1.27% for Q3 2025, versus 7.73% for Q2 2025 and 6.31% for Q1 2025.